Αποτελέσματα Αναζήτησης
7 Νοε 2022 · The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to...
25 Ιαν 2024 · Talazoparib (Talzenna) will become the NHS’s first targeted treatment for advanced breast cancers caused by mutations to BRCA genes, after a recommendation by the National Institute for Health and Care Excellence (NICE).
19 Οκτ 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show. Trastuzumab deruxtecan was also better at shrinking tumors, the DESTINY-Breast03 trial found.
14 Φεβ 2024 · A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.
23 Φεβ 2024 · We’re also keeping an eye on the new targeted breast cancer drug, capivasertib, which could treat certain patients with hormone receptor positive, HER2-negative secondary breast cancer. We’ll keep people updated with progress on drug appraisals.
21 Μαΐ 2024 · The research, published today in Clinical Cancer Research by a team from King's College London and funded by Breast Cancer Now, marks a new method in cancer treatment. The discovery is...
5 Απρ 2023 · NHS England has negotiated a commercial deal with the manufacturer, UK-based AstraZeneca, enabling the National Institute for Health and Care Excellence (NICE) to make a positive recommendation of the drug for treatment of BRCA-mutated breast and prostate cancers.
